Publication:
Real-world clinical experience of dupilumab in the treatment of chronic palmo-plantar eczema in patients with moderate-severe atopic dermatitis: 52-week follow-up

dc.contributor.authorNavarro-Triviño, Francisco José
dc.contributor.authorGalán-Gutiérrez, Manuel
dc.contributor.authorArmario-Hita, José Carlos
dc.contributor.authorRuiz-Villaverde, Ricardo
dc.contributor.authorDomínguez-Cruz, Javier
dc.contributor.authorPereyra-Rodriguez, Jose Juan
dc.contributor.authoraffiliation[Navarro-Triviño,FJ; Ruiz-Villaverde,R] Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain
dc.contributor.authoraffiliation[Galán-Gutiérrez,M] Department of Dermatology, Hospital Universitario Reina Sofía, Córdoba, Spain
dc.contributor.authoraffiliation[Armario-Hita,JC] Department of Dermatology, Hospital Universitario Puerto Real, Cádiz, Spain
dc.contributor.authoraffiliation[Domínguez-Cruz,J; Pereyra-Rodriguez,JJ] Department of Dermatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
dc.date.accessioned2025-06-12T08:57:49Z
dc.date.available2025-06-12T08:57:49Z
dc.date.issued2024-02-19
dc.description.abstractBackground: Hand-foot eczema (HFE) are special locations of dermatitis, which are often associated with atopic dermatitis (AD) and have a significant negative impact on the quality of life, demanding a clinically relevant improvement. Objectives: To evaluate the effectiveness and safety of dupilumab in the treatment of eczema localized in hands and/or feet in patients with moderate-to-severe AD. Methods: Retrospective multicenter study of adult patients with HFE treated with dupilumab for their AD. Patients with other concomitantly systemic immunosuppressive treatments did not undergo a washout period. The severity of palmar and/or plantar involvement was assessed using the Physician Global Assessment (PGA) scale on a scale of 0 ( = clear) to 5 ( = very severe). Eczema Area and Severity Index (EASI) and NRS-pruritus scales were also evaluated. One hundred percent of patients reached week 16, while 67/84 reached week 52 of follow-up. Results: A total of 84 patients were included 86.69% of patients showed a reduction in PGA-Hand, and 80.34% in PGA-Foot at week 52, EASI improvement was reached by 83.55% of patients at week 16 and 87.35% at week 52. Reduction of pruritus (≥4 points in NRS-pruritus scale) was 73.01% at week 16 and 80.67% at week 52. No differences in response to dupilumab were observed in the different subtypes of palmo-plantar dermatitis. Conclusions: The results obtained in our study suggest that dupilumab may be an effective and safe therapeutic option for the treatment of dermatitis localized in hands and/or feet.
dc.description.versionYes
dc.identifier.citationNavarro-Triviño FJ, Galán-Gutiérrez M, Hita JC, Ruiz-Villaverde R, Domínguez-Cruz J, Pereyra-Rodríguez JJ. Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up. Dermatitis. 2024 Jan-Feb;35(S1):S55-S61
dc.identifier.doi10.1089/derm.2023.0220
dc.identifier.issn1710-3568 / 2162-5220)
dc.identifier.urihttps://hdl.handle.net/10668/28525
dc.journal.titleDermatitis
dc.language.isoen
dc.page.numberS55-S61
dc.publisherMary Ann Liebert, Inc Publishers
dc.relation.publisherversionhttps://www.liebertpub.com/doi/10.1089/derm.2023.0220
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectDupilumab
dc.subjectAtopic Dermatitis
dc.subjectHand Eczema
dc.subjectFoot Eczema
dc.subjectReal-world Evidence
dc.subject.decsDermatitis Atópica
dc.subject.decsEccema
dc.subject.decsManos
dc.subject.decsPies
dc.subject.decsAnticuerpos Monoclonales Humanizados
dc.subject.meshDermatitis, Atopic
dc.subject.meshEczema
dc.subject.meshHands
dc.subject.meshFeet
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.titleReal-world clinical experience of dupilumab in the treatment of chronic palmo-plantar eczema in patients with moderate-severe atopic dermatitis: 52-week follow-up
dc.typeresearch article
dc.type.hasVersionAM
dc.volume.number35
dspace.entity.typePublication
relation.isAuthorOfPublication47317875-9523-4829-94ac-769b6ae49c50
relation.isAuthorOfPublication.latestForDiscovery47317875-9523-4829-94ac-769b6ae49c50

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
NavarroTrivino_Realworld.pdf
Size:
696.14 KB
Format:
Adobe Portable Document Format